New trials, publications, preprints and grants on this target, month by month.
Trial
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
1 May 2028· NA · NOT_YET_RECRUITING· CTGOV
Trial
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
1 Mar 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer. Reply.
5 Nov 2026· The New England journal of medicine· PUBMED
Publication
Corrigendum to "Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients" [J. Pharmaceut. Biomed. Anal. 237 (2024) 115758].
5 Nov 2026· Journal of pharmaceutical and biomedical analysis· PUBMED
Publication
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
5 Nov 2026· The New England journal of medicine· PUBMED
Publication
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
5 Nov 2026· The New England journal of medicine· PUBMED
Publication
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
5 Nov 2026· The New England journal of medicine· PUBMED
Publication
Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency.
3 Nov 2026· Molecular cancer therapeutics· PUBMED
Trial
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer.
1 Nov 2026· Clinical and translational medicine· PUBMED
Publication
BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer.
28 Oct 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.
27 Oct 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Phytochemical and biological investigation of Galium sinaicum: Cytotoxic constituents with in vitro PARP-1 inhibitory activity.
24 Oct 2026· Fitoterapia· PUBMED
Publication
Functional biomarkers complementing static BRCA/HRD testing for dynamic PARP inhibitor therapy in ovarian cancer: a narrative review.
13 Oct 2026· Frontiers in oncology· PUBMED
Publication
Multi-cohort screening of PANoptosis-related genes reveals PARP1 as a key target, and AZD5305 exerts anti-tumor effects in neuroblastoma.
12 Oct 2026· Frontiers in oncology· PUBMED
Publication
Synthesis and Preliminary Biological Evaluation of a Structurally Modified Niraparib-Based PARP-Targeted PET Tracer for Tumor Imaging.
9 Oct 2026· ACS omega· PUBMED
Trial
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
8 Oct 2026· PHASE2 · RECRUITING· CTGOV
Publication
Discovery of Dual PARP/GPX4 Inhibitors for the Treatment of Triple-Negative Breast Cancer.
8 Oct 2026· Journal of medicinal chemistry· PUBMED
Publication
A Platinum(IV)-Ursolic Acid Conjugate Overcomes Cisplatin Resistance in Ovarian Cancer by Targeting XPO1 and PARP1.
8 Oct 2026· Journal of medicinal chemistry· PUBMED
Trial
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
7 Oct 2026· PHASE3 · RECRUITING· CTGOV
Publication
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.
7 Oct 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Hybrid surgical thromboembolectomy and crossover endovascular revascularization for acute lower-limb ischemia in a patient with active ovarian cancer receiving a PARP inhibitor (fuzuloparib): a case report and literature review.
7 Oct 2026· Frontiers in cardiovascular medicine· PUBMED
Publication
Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers.
1 Oct 2026· Cancer medicine· PUBMED
Publication
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
1 Oct 2026· The Journal of clinical investigation· PUBMED
Publication
Long-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinoma.
28 Sept 2026· Pharmaceuticals (Basel, Switzerland)· PUBMED
Publication
Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer to PARP Inhibitors.
28 Sept 2026· Cancer research· PUBMED
Publication
Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
25 Sept 2026· Cancers· PUBMED
Publication
Hit It before It Starts: Targeting a (3 + 1) Hybrid Non-canonical G-Quadruplex to Silence PARP1 in Cancer.
24 Sept 2026· Journal of medicinal chemistry· PUBMED
Publication
A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib.
24 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
FANCD2 knockdown suppresses malignant phenotypes and is associated with caspase/PARP-mediated apoptosis in NCI-H2052 pleural mesothelioma cells.
23 Sept 2026· Frontiers in genetics· PUBMED